Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

Background. Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Objective. Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and I...

Full description

Bibliographic Details
Main Authors: Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, Elona Begvarfaj, Francesca Cascone, Giacomo Alfonzo, Rosalba Cadeddu, Stefano Millarelli, Gianluca Bellocchi, Antonio Greco, Marco de Vincentiis, Simonetta Masieri
Format: Article
Language:English
Published: Hindawi Limited 2023-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2023/4027701

Internet

http://dx.doi.org/10.1155/2023/4027701

Similar Items